ES2751300T3 - Formulación sublingual de riluzol - Google Patents
Formulación sublingual de riluzol Download PDFInfo
- Publication number
- ES2751300T3 ES2751300T3 ES15823415T ES15823415T ES2751300T3 ES 2751300 T3 ES2751300 T3 ES 2751300T3 ES 15823415 T ES15823415 T ES 15823415T ES 15823415 T ES15823415 T ES 15823415T ES 2751300 T3 ES2751300 T3 ES 2751300T3
- Authority
- ES
- Spain
- Prior art keywords
- riluzole
- approximately
- sublingual
- minutes
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims abstract description 144
- 229960004181 riluzole Drugs 0.000 title claims abstract description 140
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 238000009472 formulation Methods 0.000 title claims abstract description 80
- 239000000651 prodrug Substances 0.000 claims abstract description 26
- 229940002612 prodrug Drugs 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000012453 solvate Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims abstract description 6
- 239000004067 bulking agent Substances 0.000 claims abstract description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 5
- 229930195725 Mannitol Natural products 0.000 claims abstract description 5
- 239000000594 mannitol Substances 0.000 claims abstract description 5
- 235000010355 mannitol Nutrition 0.000 claims abstract description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000000600 sorbitol Substances 0.000 claims abstract description 4
- 238000001179 sorption measurement Methods 0.000 claims abstract description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 66
- 208000035475 disorder Diseases 0.000 description 41
- 231100000862 numbness Toxicity 0.000 description 36
- 230000000694 effects Effects 0.000 description 31
- 238000000034 method Methods 0.000 description 27
- 201000010099 disease Diseases 0.000 description 25
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 210000000214 mouth Anatomy 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 208000019901 Anxiety disease Diseases 0.000 description 14
- 206010031009 Oral pain Diseases 0.000 description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000036506 anxiety Effects 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 208000010877 cognitive disease Diseases 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 208000028017 Psychotic disease Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 208000035824 paresthesia Diseases 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- -1 anomers Chemical class 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 208000022821 personality disease Diseases 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 206010002942 Apathy Diseases 0.000 description 6
- 206010013142 Disinhibition Diseases 0.000 description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 description 6
- 206010022998 Irritability Diseases 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 206010038743 Restlessness Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 208000027061 mild cognitive impairment Diseases 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000016686 tic disease Diseases 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- 206010016352 Feeling of relaxation Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 201000006347 Intellectual Disability Diseases 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000027520 Somatoform disease Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000013043 chemical agent Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 208000027753 pain disease Diseases 0.000 description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 206010012239 Delusion Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000030814 Eating disease Diseases 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 208000036626 Mental retardation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010049816 Muscle tightness Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010034568 Peripheral coldness Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010048327 Supranuclear palsy Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000036626 alertness Effects 0.000 description 3
- 231100000868 delusion Toxicity 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000027691 Conduct disease Diseases 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 206010018286 Gingival pain Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 208000020358 Learning disease Diseases 0.000 description 2
- 206010062038 Lip neoplasm Diseases 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000006289 Rett Syndrome Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 206010007776 catatonia Diseases 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 208000030251 communication disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000035548 disruptive behavior disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000014616 embryonal neoplasm Diseases 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 206010050013 Abulia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 101710125610 Adenosine receptor A2a Proteins 0.000 description 1
- 102100035990 Adenosine receptor A2a Human genes 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000030336 Bipolar and Related disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010061020 Breast cancer male Diseases 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008399 Change of bowel habit Diseases 0.000 description 1
- 208000027521 Childhood-Onset Fluency disease Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 208000024581 Compulsive Personality disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032538 Depersonalisation Diseases 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 208000025967 Dissociative Identity disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000021661 Elimination disease Diseases 0.000 description 1
- 208000000271 Encopresis Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 208000016619 Histrionic personality disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 101710093458 ICOS ligand Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028193 Multiple endocrine neoplasia syndromes Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000027120 Narcissistic personality disease Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010057372 Paraesthesia oral Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010034432 Performance fear Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000025890 Social Communication disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000021392 Specific Learning disease Diseases 0.000 description 1
- 208000014584 Specific learning disability Diseases 0.000 description 1
- 208000028790 Speech Sound disease Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023655 Tic Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 208000027568 Trauma and Stressor Related disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 208000022804 avoidant personality disease Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000030964 dependent personality disease Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000027881 multiple personality disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 208000012198 paraphilic disease Diseases 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940072169 rilutek Drugs 0.000 description 1
- 229940096364 riluzole 50 mg Drugs 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2751300T3 true ES2751300T3 (es) | 2020-03-31 |
Family
ID=55085882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15823415T Active ES2751300T3 (es) | 2014-11-21 | 2015-11-17 | Formulación sublingual de riluzol |
| ES19186196T Active ES2882783T3 (es) | 2014-11-21 | 2015-11-17 | Formulación sublingual de riluzol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19186196T Active ES2882783T3 (es) | 2014-11-21 | 2015-11-17 | Formulación sublingual de riluzol |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (enExample) |
| EP (3) | EP3220891B1 (enExample) |
| JP (3) | JP6753860B2 (enExample) |
| KR (2) | KR102811263B1 (enExample) |
| CN (1) | CN107249567B (enExample) |
| AU (2) | AU2015350148B2 (enExample) |
| BR (1) | BR112017010423B1 (enExample) |
| CA (1) | CA2967662A1 (enExample) |
| CY (1) | CY1122469T1 (enExample) |
| DK (1) | DK3220891T3 (enExample) |
| EA (1) | EA038518B1 (enExample) |
| ES (2) | ES2751300T3 (enExample) |
| HR (1) | HRP20191892T8 (enExample) |
| HU (1) | HUE046869T2 (enExample) |
| IL (2) | IL278188B2 (enExample) |
| LT (1) | LT3220891T (enExample) |
| MX (1) | MX368838B (enExample) |
| PH (1) | PH12017500934B1 (enExample) |
| PL (1) | PL3220891T3 (enExample) |
| PT (1) | PT3220891T (enExample) |
| RS (1) | RS59490B1 (enExample) |
| SG (1) | SG11201703896QA (enExample) |
| SI (1) | SI3220891T1 (enExample) |
| WO (1) | WO2016081472A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE070289T2 (hu) | 2016-10-11 | 2025-05-28 | Arvinas Operations Inc | Vegyületek és módszerek az androgénreceptor célzott lebontására |
| JP7354123B2 (ja) * | 2018-02-21 | 2023-10-02 | エイアイ・セラピューティクス・インコーポレーテッド | アピリモドとグルタミン酸作動薬を用いた併用療法 |
| BR112020023231A2 (pt) * | 2018-05-27 | 2021-02-23 | Biohaven Pharmaceutical Holding Company Ltd. | uso de comprimidos desintegrantes orais de riluzol para tratamento de doenças |
| MX2021001563A (es) * | 2018-08-16 | 2021-06-15 | Biohaven Therapeutics Ltd | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. |
| JP7716396B2 (ja) * | 2019-10-22 | 2025-07-31 | アルビナス・オペレーションズ・インコーポレイテッド | 前立腺癌を治療する方法 |
| MX2022014071A (es) | 2020-05-09 | 2023-01-30 | Arvinas Operations Inc | Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo. |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| WO2022103634A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| JP3233638B2 (ja) | 1993-07-09 | 2001-11-26 | アール．ピー． シェーラー コーポレイション | 凍結乾燥された薬投与形状物の製造方法 |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) * | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| NZ336326A (en) * | 1996-12-20 | 2001-02-23 | Nutrinova Gmbh | Method for increasing the sweetening power and enhancing the taste of a mixture of extremely powerful sweetening agents |
| JP4563516B2 (ja) | 1997-02-20 | 2010-10-13 | マサチューセッツ インスティテュート オブ テクノロジー | 迅速分散性を示す投与剤形、その使用法並びにその製造方法 |
| PT1001748E (pt) | 1997-07-25 | 2006-08-31 | Alpex Pharma Sa | Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca |
| HK1042856B (zh) | 1998-11-20 | 2007-07-27 | Skyepharma Canada Inc. | 可分散的磷脂稳定的微粒 |
| JP2002531490A (ja) * | 1998-12-09 | 2002-09-24 | カイロン コーポレイション | 中枢神経系に薬剤を投与するための方法 |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| DE60222160T2 (de) | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| AU2003211051A1 (en) | 2002-02-13 | 2003-09-04 | Michael K. Weibel | Drug dose-form and method of manufacture |
| EP2316469A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| AU2005218625A1 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| WO2009002084A2 (en) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
| WO2010009279A1 (en) * | 2008-07-15 | 2010-01-21 | University Of Medicine And Dentistry Of New Jersey | Methods and compositions for treating alzheimer's disease |
| US8731842B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8256233B2 (en) | 2008-10-31 | 2012-09-04 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| ES2665569T3 (es) * | 2011-03-01 | 2018-04-26 | Pharnext | Tratamiento de la isquemia cerebral |
| US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| UA115968C2 (uk) * | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| EP2731611B1 (en) * | 2011-07-13 | 2019-09-18 | Cytokinetics, Inc. | Combination therapie for als |
| CA3075331A1 (en) * | 2012-03-01 | 2013-09-06 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| EA201791110A1 (ru) | 2014-11-21 | 2017-11-30 | Биохэвен Фармасьютикэл Холдинг Компани Лтд. | Сублингвальное введение рилузола |
| EP3265448B1 (en) * | 2015-03-03 | 2021-12-29 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
-
2015
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2751300T3 (es) | Formulación sublingual de riluzol | |
| ES2981830T3 (es) | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres | |
| ES2985986T3 (es) | Conjugado biciclo para tratar el cáncer | |
| EP3220890A1 (en) | Sublingual administration of riluzole | |
| ES2898771T3 (es) | Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales | |
| ES2909234T3 (es) | Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk | |
| CN108042542A (zh) | 用于治疗病症的方法和组合物 | |
| JP2018509460A (ja) | 炎症疾患及び免疫疾患を治療するための方法及び組成物 | |
| IL202237A (en) | Use of 7– (2, 5– dihydro-4 – imidazo [2,1– a] pyridine – 3 – il – 5,2 – dioxo – i– pyrrole – 3 – il (–9 – fluoro – 4,3, 2,1-tetrahydro-2 (1-piperidinyl-carbonyl-pyrrolo [1,2,3-jk] [4,1] Benzodiazepine or a salt suitable for its pharmaceutical preparation for use in combination with a chemotherapeutic agent | |
| KR20200055116A (ko) | Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
| HK40077183A (en) | Sublingual formulation of riluzole | |
| HK40024978B (en) | Sublingual formulation of riluzole | |
| HK40024978A (en) | Sublingual formulation of riluzole | |
| HK1243318B (en) | Sublingual formulation of riluzole | |
| HK1243318A1 (en) | Sublingual formulation of riluzole | |
| HK40028225B (zh) | 戊二酰亚胺衍生物用於治疗与细胞因子的异常活性相关的疾病的用途 |